Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia
1 other identifier
interventional
20
1 country
1
Brief Summary
The investigators plan to conduct a clinical trial to assess the effects and safety of platelet rich plasma on androgenetic alopecia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 25, 2014
CompletedFirst Posted
Study publicly available on registry
February 28, 2014
CompletedStudy Start
First participant enrolled
April 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedDecember 11, 2014
December 1, 2014
1.2 years
February 25, 2014
December 10, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The degree of hair regrowth based on the hair regrowth score (RGS) for each side of scalp.
16 weeks
Secondary Outcomes (1)
Changes in hair count and caliber. Changes in hair count and caliber
16 weeks
Study Arms (1)
PRP/Saline
EXPERIMENTALSame patient will be injected with PRP and normal saline. Each one will be inject on half head.
Interventions
PRP will be inject to half head. The other half will be injected with normal saline.
Eligibility Criteria
You may qualify if:
- Males and females in good general health, ages 18-70.
- Patients with mild to moderate AGA (Ludwig alopecia score I and II, and the Hamilton-Norwood score 1 to 4).
You may not qualify if:
- Patients who received treatments for AGA within the last 3 months.
- Patients who have active or history of malignancies.
- Patients with platelets disorders, anemia and or bleeding disorders.
- Women who are pregnant or breast-feeding.
- Un-cooperative patients or patients who are unable to understand the protocol or give informed consent.
- Patients who are known to be HIV, hepatitis B or C positive or otherwise immunocompromised.
- Subjects who have active skin disease or skin infection at the intended treatment area.
- Patients on non-steroidal anti-inflammatory medications.
- Patients with a propensity for keloids.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Skin Care Center, Vancouver General Hospital
Vancouver, V5Z 4E8, Canada
Related Publications (1)
Siah TW, Guo H, Chu T, Santos L, Nakamura H, Leung G, Shapiro J, McElwee KJ. Growth factor concentrations in platelet-rich plasma for androgenetic alopecia: An intra-subject, randomized, blinded, placebo-controlled, pilot study. Exp Dermatol. 2020 Mar;29(3):334-340. doi: 10.1111/exd.14074. Epub 2020 Feb 7.
PMID: 31984508DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jerry Shapiro, MD
Professor
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
February 25, 2014
First Posted
February 28, 2014
Study Start
April 1, 2014
Primary Completion
June 1, 2015
Study Completion
December 1, 2015
Last Updated
December 11, 2014
Record last verified: 2014-12